TCL Archive Small Phase II Study Finds New Oral Agent May Slow Progression Of Difficult Cancer April 24, 2009
TCL Archive Tasigna Shows High Response, PFS Benefit Compared to Gleevec in Phase III CML Study December 26, 2014